Tag #Ftc Report

What are the immediate, quantifiable effects of PBM pricing practices on patient costs and the overall pharmaceutical market?

The FTC's report accuses Pharmacy Benefit Managers (PBMs) of significantly increasing specialty generic drug prices, exceeding acquisition costs by over \$7.3 billion from 2017-2022 and using spread pricing to generate an additional \$1.4 billion. This practice, coupled with preferential reimbursement to affiliated pharmacies, directly increases patient out-of-pocket costs and contributes to rising pharmaceutical expenses.